Nicotine use in mental illness and neurological disorders / Mariella De Biasi.

Format:

Book

Author/Creator:

De Biasi, Mariella, author.

Contributor:

De Biasi, Mariella, editor.

Series:

International review of neurobiology ; Volume 124.

International Review of Neurobiology, 0074-7742 ; Volume 124

Language:

English

Subjects (All):

Mental illness--Treatment.

Mental illness.

Tobacco--Therapeutic use.

Tobacco.

Nicotine--Therapeutic use.

Nicotine.

Physical Description:

1 online resource (0 p.)

Edition:

First edition.

Place of Publication:

Amsterdam, [The Netherlands] : Elsevier, 2015.

Summary:

Nicotine Use in Mental Illness and Neurological Disorders, a volume in the International Review of Neurobiology series, is a comprehensive overview of the state-of-the-art research into nicotine use in mental illness and neurological disorders. It reviews current knowledge and understanding, also provides a starting point for researchers and practitioners entering the field.-- Source other than Library of Congress.

Contents:

Front Cover

Nicotine Use in Mental Illness and Neurological Disorders

Copyright

Contents

Contributors

Preface

Part 1: Introductory chapter

Chapter One: Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine

1. Introduction

2. Nicotinic Receptor Structure

3. Nicotinic Receptor Channel Gating

4. Cationic Permeability of the Nicotinic Receptor Pore

5. Nicotinic Receptor Response to Nicotine from Tobacco

6. Conclusion

Acknowledgment

References

Part 2: Schizophrenia

Chapter Two: The Role of Nicotine in Schizophrenia

1.1. Schizophrenia

1.2. Nicotine and Schizophrenia

2. Effects of Nicotine on Schizophrenia Endophenotypes and Symptom Domains

2.1. Electrophysiological Measures

2.1.1. P50 Sensory Gating

2.1.1.1. Effects of Nicotine on P50 Gating

2.1.1.2. P50 Gating as a Predictor of Disease-Related Symptoms

2.1.2. Mismatch Negativity

2.1.2.1. Effects of Nicotine on MMN

2.1.2.2. MMN as a Predictor of Disease-Related Symptoms

2.1.3. P300

2.1.3.1. Effects of Nicotine on P300

2.1.3.2. P300 as a Predictor of Disease-Related Symptoms

2.2. Cognition

2.3. Disease-Related Symptoms

2.4. Conclusions

3. Nicotinic Receptor Genes in Schizophrenia

3.1. Canonical Nicotinic-Binding Sites

3.1.1. CHRNA7

3.1.2. CHRNA4-CHRNB2

3.1.2.1. CHRNB2

3.1.2.2. CHRNA4

3.2. Noncanonical Nicotinic-Binding Sites

3.2.1. CHRNA5-CHRNA3-CHRNB4

3.2.1.1. CHRNA5

3.2.1.2. CHRNA3

3.2.1.3. CHRNB4

3.2.2. CHRNA6-CHRNB3

3.2.3. CHRNA2

3.2.4. Conclusions

4. Development of Nicotinic Agents for the Treatment of Schizophrenia

4.1. α7

4.1.1. Sensory Gating

4.1.2. MMN/P300

4.1.3. Disease-Related Symptoms

4.1.4. Cognition

4.1.4.1. Attention

4.1.4.2. Working Memory

4.1.4.3. Long-Term Memory.

4.1.5. Conclusions

4.2. α4β2

4.2.1. Sensory Gating

4.2.2. MMN/P300

4.2.3. Disease-Related Symptoms

4.2.4. Cognition

4.2.4.1. Attention

4.2.4.2. Working Memory

4.2.4.3. Long-Term Memory

4.3. Other Receptor Subtypes

5. Conclusions

Chapter Three: Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia

2. The α7 nAChRs

3. The Heteromeric α7-Containing Receptors

4. Localization of the α7 Receptors

5. Allosteric Modulation

6. The α7 Receptors in Brain Circuits

7. α7 Receptors and Schizophrenia

8. α7 and NMDA Receptor Interactions in Schizophrenia

9. α7 Receptors as a Drug Target

9.1. The Agonist Approach

9.2. The Allosteric Modulation Approach

9.3. α7 Receptor Priming

10. Effects of α7-Selective Compounds on Behavior

10.1. Clinical Trials: Cognition

10.2. Clinical Trials: Negative Symptoms

11. Conclusions

Chapter Four: Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders

2. Known Mechanisms of Neuregulin-ErbB Signaling

2.1. Overview

2.2. Neuregulin Binding and ErbB Dimerization

2.3. Effects of Alternative Splicing of the ErbB4 Receptor

2.4. Neuregulin-ErbB4 Effects on NMDA Receptors

2.5. Acetylcholine Receptor Inducing Activity: Modulation of nAChR Expression

3. NRG3: Relevance in Smoking Behavior and Co-morbid Disorders

3.1. Potential Role of NRG3 in Nicotine Withdrawal and Smoking Cessation Outcome

3.2. NRG3 in Schizophrenia

3.3. NRG3: Possible Mechanisms Underlying Co-morbidity

4. ERBB4: Relevance in Smoking Behavior and Co-morbid Disorders

4.1. Association Between ERBB4 and Nicotine Dependence

4.2. ErbB4-NMDA Receptor Interactions in Schizophrenia and Possible Relevance for Co-morbidity with Nicotine Dependence.

5. Summary

Chapter Five: Effective Cessation Strategies for Smokers with Schizophrenia

1. Efficacy of Bupropion, as Monotherapy or in Combination with NRT

2. Efficacy of Varenicline

3. Duration of Treatment

4. Behavioral Treatment

5. Treatment Adherence

6. Safety Issues

7. Conclusion

Part 3: Mood disorders

Chapter Six: Role of the Brain´s Reward Circuitry in Depression: Transcriptional Mechanisms

2. The NAc Reward Circuit in Mood Regulation

3. Transcriptional and Epigenetic Mechanisms in the NAc in Mood Regulation

3.1. CREB-Mediated Transcription in the NAc in Mood Regulation

3.2. △FosB and SRF in the NAc Pathway in Mood Regulation

3.3. Other Transcription Factors in the NAc in Mood Regulation

3.4. Epigenetic Mechanisms in the NAc in Mood Regulation

3.5. Identification and Characterization of Target Genes for Specific Transcription Factors in the NAc

4. Future Directions

Chapter Seven: Nicotine Addiction and Psychiatric Disorders

2. Nicotine´s Effects on ADHD

2.1. Relationship Between Nicotine Exposure and ADHD in Humans

2.2. Effects of Nicotine on Animal Models of ADHD

2.3. Developmental Nicotine Exposure and Its Effects on ADHD

3. Involvement of nAChRs in Anxiety and Anxiety Disorders

3.1. Relationship Between Nicotine Exposure and Anxiety Disorders in Humans

3.2. Effects of Nicotine on Animal Models of Anxiety Disorders

4. Effects of Nicotine Dependence, Withdrawal, and nAChR Regulation on Depression

4.1. The Relationship Between Nicotine Dependence and Depression in Humans

4.2. Effects of Nicotine on Animal Models of Depression

5. Conclusion

References.

Chapter Eight: The Role of Depression in the Uptake and Maintenance of Cigarette Smoking

1. The Smoking and Depression Problem

2. Adolescent Smoking Uptake and Depression

2.1. How Does Adolescent Depression Influence Smoking Uptake?

2.2. Which Adolescents Are More Vulnerable?

2.3. Clinical Implications

3. Smoking Cessation and Depression

3.1. Smoking Cessation Treatment Outcomes in Smokers with Depression

3.2. Behavioral Therapy for Smoking Cessation: Mood Management

3.3. Pharmacotherapy for Smoking Cessation

3.4. Summary

4. Targeting Positive Mood May Increase Smoking Cessation Treatment Effectiveness

5. Individual Differences in Cessation Outcome and Treatment Effectiveness

6. Conclusions

Part 4: Parkinson's disease

Chapter Nine: Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson´s Disease and Drug-Induced Movement Disorders

1. Parkinson´s Disease Overview

2. Neuroprotection and Parkinson´s Disease

2.1. Decreased Incidence of Parkinson´s Disease with Smoking

2.2. Role for the Nicotinic Cholinergic System in Neuroprotection

3. Nicotine and nAChR Drugs Do Not Improve Parkinsonian Motor Symptoms

4. Nicotine and nAChR Drugs Reduce LIDs

4.1. LIDs Overview

4.2. Nicotine Decreases LIDs

4.3. nAChRs That Mediate the Antidyskinetic Effect of Nicotine

4.3.1. General nAChR Drugs Reduce LIDs

4.3.2. β2* nAChR Agonists Attenuate LIDs

4.3.3. α7 nAChR Agonist Decreases LIDs

5. Nicotine and nAChR Drugs Reduce Antipsychotic-Induced Tardive Dyskinesias

5.1. Tardive Dyskinesia Overview

5.2. Nicotine Reduces Tardive Dyskinesia by Acting at nAChRs

6. Beneficial Role of Nicotine and nAChR Drugs in Cognition, Depression, and Other Neuropsychiatric Disorders

7. Concluding Remarks

Part 5: Alzheimer's disease

Chapter Ten: Nicotinic Cholinergic Mechanisms in Alzheimer´s Disease

1. Homomeric and Heteromeric α7-nAChRs

2. Alterations of α7-nAChR Expressions in AD Animal Models and AD Patients

3. Interaction of Amyloid Beta Peptides (Aβ) and α7-nAChRs

4. Coincident Roles of α7-nAChRs in Aβ Toxicity

5. Roles of α7-nAChRs in Neuronal Hyperexcitation in AD

6. Coincident Roles of α7-nAChRs in AD Pathogenesis

7. Conclusions

Index

Contents of Recent Volumes

Back Cover.

Notes:

Includes index.

Description based on online resource; title from PDF title page (ebrary, viewed December 01, 2015).

ISBN:

9780128015834

0128015837

9780128016268

0128016264

OCLC:

929522866